All News

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma.

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric patients with T-ALL and T-LBL.

Dr. Ariel Ostad explains how addressing uncertainty and scananxiety through communication and support can improve the cancer care experience for patients.

Dr. Tracy Proverbs-Singh explains how a multidisciplinary team helps patients with GI cancers manage digestion, absorb nutrients and maintain energy during treatment.

Kim Johnson shares her experience losing her sister to cancer, offering guidance for those grieving and for the people supporting them.

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer.

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

The NCCN Clinical Practice Guidelines in Oncology now include Besremi as a Category 1 preferred treatment option for some with high-risk essential thrombocythemia.

Dr. Anne Peled, a two-time breast cancer survivor, underwent a sensation-preserving mastectomy, a procedure she co-developed.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.

Dr. Anne Peled shares advice for patients and dispelled myths related to cancer survivorship.

If you’re struggling out there, feeling a little broken inside, I see you. And if you’re not, man, I wish I were you.

As patients with advanced cancer near the end of life, reducing unnecessary medications may help prioritize comfort, quality of life and symptom relief.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

This weekend, January 30 - February 1, join thousands of runners, walkers, survivors and spectators for the 19th Annual DONNA Marathon Weekend.

Among patients with advanced breast cancer, levels of circulating tumor DNA before treatment may predict their response to targeted therapy.

Patients with recurrent or progressive high-grade meningioma had encouraging responses to Verzenio in a phase 2 trial.

A 27-year brain tumor survivor shares how mindset, resilience and purposeful action helped her thrive beyond what cancer statistics predicted.

Researchers sought to address a critical gap in the health care system where 85% of U.S. children diagnosed with cancer survive at least five years.

The FDA cleared a phase 3 trial of iSCIB1+ for advanced melanoma after phase 2 data showed improved progression free survival versus standard care.

Stage 2 essential thrombocythemia is a slow-growing blood cancer managed with monitoring or treatment to reduce clot risk and control symptoms.

Newly diagnosed with cancer? This oncofertility guide covers egg freezing, sperm banking, and critical questions for your oncologist.

Receiving a diagnosis of squamous cell carcinoma can be an overwhelming experience, but it is important to remember that you are not alone.

Small cell lung cancer grows quickly. Learn how it’s diagnosed, staged and treated, and what patients can expect from therapies and side effects.

Patients should understand their cancer, treatment goals and options and record questions to support informed, productive discussions with care teams.

For Ashliann Mazeika, a diagnosis at 24 led to a decade-long treatment journey affirmed by the Breast Cancer Index test.

After five years in remission, a scan shows a small anomaly that might be recurrence, or it can show nothing, leaving a tense week before my oncologist visit.

FDA granted breakthrough therapy designation to sofetabart mipitecan for adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.